Reduction of Burn Progression and Scar Contracture with Cytokine-Neutralizing Gels

Award Information
Agency:
Department of Defense
Branch
Defense Health Program
Amount:
$150,000.00
Award Year:
2013
Program:
SBIR
Phase:
Phase I
Contract:
W81XWH-13-C-0050
Agency Tracking Number:
H122-016-0039
Solicitation Year:
2012
Solicitation Topic Code:
DHP12-016
Solicitation Number:
2012.2
Small Business Information
Washburn Therapeutics, Inc.
6743 Wilkins Ave., Pittsburgh, PA, -
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
803136758
Principal Investigator:
Newell Washburn
President
(412) 908-1309
newell.washburn@gmail.com
Business Contact:
Newell Washburn
President
(412) 908-1309
newell.washburn@gmail.com
Research Institution:
Stub




Abstract
Washburn Therapeutics Inc. is developing biologically active gels that control inflammation by selectively neutralizing pro-inflammatory cytokines based on a technology being licensed exclusively by the company from Carnegie Mellon University. Preliminary results demonstrated that conjugates of antibodies against tumor necrosis factor-alpha and hyaluronic acid were able to reduce secondary necrosis in a partial-thickness rat burn model by 70%. This SBIR Phase I will focus on treating partial-thickness burns to test of the safety and efficacy of the technology in preventing extensive tissue necrosis following burn and measuring subsequent scar contraction in the rat burn model. The hypothesis of this research program is that prevention of burn progression through local control of inflammatory responses will improve healing outcomes. Early therapeutic intervention could make a significant impact in burn treatment.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government